Immunovant, Inc. ($IMVT) — A short review ahead of its anticipated Phase 2 topline clinical readout for IMVT-1402 indicated for Cutaneous Lupus (CLE).

Immunovant, Inc. ($IMVT) — A short review ahead of its anticipated Phase 2 topline clinical readout for IMVT-1402 indicated for Cutaneous Lupus (CLE). **Overview of Cutaneous Lupus (CCLE):** * CLE is a rare, long-lasting autoimmune skin disorder characterised by persistent inflammation, visible skin activity, and eventual tissue damage. * Sunlight is a major trigger: patients develop characteristic rashes and painful lesions, often accompanied by itching, burning sensations, and hair loss. * According to IMVT, in the US, SCLE and CCLE together affect an estimated \~153,000 people, with roughly half failing to respond adequately to standard therapies — leaving \~75,000 patients with significant unmet medical need. **Current Treatment Landscape:** * There is currently no cure. * Initial management relies on photoprotection, topical corticosteroids, and broad immunomodulatory agents such as DMARDs, antimalarials, and systemic steroids. * More refractory cases may require IVIg or off‑label biologics. * Around 50% of patients remain insufficiently controlled — due to weak response, frequent relapse, or limitations of antimalarials (including retinopathy risk). **Overview of IMVT-1402 and the Phase 2 Clinical Trial:** **IMVT-1402** is an investigational **anti-FcRn antibody** engineered to **lower circulating IgG** with high potency while avoiding the safety liabilities seen in earlier FcRn inhibitors. FcRn has an important job in the body: it protects IgG antibodies from being broken down and recycles them back into circulation. That includes normal protective IgG antibodies, as well as potentially harmful IgG autoantibodies. In **Lupus**, the immune system can produce autoantibodies that mistakenly target the body's own tissues. These antibodies can form immune complexes, triggering inflammation and contributing to tissue damage. Hence, IMVT-1402’s mechanistic rationale can be simplified as attempting to **block FcRn**, which **prevents efficient IgG recycling**, leading to more **IgG degradation** and, therefore, a **fall in circulating IgG levels**. IMVT-1402 reduces the amount of pathogenic IgG autoantibodies available to drive autoimmune disease. The Phase 2 Trial (on [http://clinicaltrials.gov](http://clinicaltrials.gov)): The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus. **Trial Design** * Three‑period structure (total ≈61 weeks per participant) * Period 1 (12 weeks): Randomised 1:1 to IMVT‑1402 (Dose 1) or placebo, given subcutaneously once weekly. * Period 2 (14 weeks): All participants switch to open‑label IMVT‑1402 (Dose 1) weekly. * Period 3 (26 weeks): Participants are re-randomised 1:1 to Dose 1 vs. Dose 2, both blinded. * Masking: Double‑blind for Periods 1 and 3 (participant + investigator). * Model: Parallel assignment. * Enrollment: \~56 participants across 86 global sites. **Key Eligibility Criteria** * Biopsy‑confirmed SCLE or CCLE. * CLASI‑A ≥10 at screening/day 1 (or ≥8–<10 if no alopecia/mucosal lesions). * Active disease despite adequate trials of standard therapies. * Positive for at least one autoantibody. * Excludes drug‑induced CLE, neuropsychiatric SLE, rapidly progressive nephritis, or confounding skin diseases. **Timeline** * Study start: February 2025 * Primary completion (estimated): October 2026 Study completion (estimated): April 2027 **Primary Endpoint (Week 12)** Per cent change in CLASI‑A score from baseline. * CLASI‑A is the validated measure of CLE skin activity (0–70 scale). **Secondary Endpoints (Week 12)** * Proportion achieving ≥5‑point reduction in CLASI‑A. * Proportion achieving ≥50% reduction in CLASI‑A. * Proportion achieving ≥70% reduction in CLASI‑A. **Analyst Thesis Overview: a 65-70% PoS and positive topline readout.** Beyond Immunovant, the mechanistic rationale and biology of IMVT-1402 have already been somewhat strongly validated by **Nipocalimab** in **Systemic lupus erythematosus (SLE)** in the **Phase 2 JASMINE trial by Johnson & Johnson**. Although I understand SLE is completely different to CLE, I believe this treatment has the potential to be generally effective across the broad Lupus family. Nipocalimab is a different molecule from IMVT-1402, but are testing the same fundamental therapeutic hypothesis. More can be read about the results of the JASMINE trial from the Johnson & Johnson website, but the key details were that it was **a positive readout**: * It showed **clinical efficacy against placebo**. * Interestingly, the signal was particularly strong in a predefined autoantibody-positive population, as expected, since this is the population where the FcRn mechanism should be most relevant in theory. In IMVT’s own trial, eligible participants are screened if they have at least one autoantibody. Immunovant already has its own early CLE proof-of-concept data validating IMVT-1402’s mechanistic rationale. In a small, open-label study, one patient with severe SCLE received weekly IMVT-1402 for 12 weeks. The patient reportedly experienced: * Approximately 78% reduction in total IgG * A reduction in CLASI-A from 36 to 13 * A greater than 60% improvement in skin disease activity A second patient reportedly improved from a CLASI-A score of 18 to 8 after 12 weeks. These are important clinical improvements. However, I do recognise that this was a small trial with a small patient population, without a placebo control, and was open-label. However, overall, I hold a measured view that Immuvant’s Phase trial in CLE will be positive. **Important Note:** Immunovant is **55%** owed by **Roviant Ltd. ($ROIV)**. However, this doesn’t change much, if anything, an investor might consider investing in both stocks, although I’d personally just invest in Immunovant to get direct exposure to the stock ahead of its catalyst and if this is the only catalyst you are interested in being part of. In the lead up to Q4, I expect this stock to maybe have a run-up but it won’t be much. After the readout, I’m looking between \~$45-$50 as my target price, therefore roughly a \~35% change from its current price (\~$37). Resources I used for research: [https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000092/imvt-20250331.htm?utm\_source=chatgpt.com](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000092/imvt-20250331.htm?utm_source=chatgpt.com) [https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/eular/nipocalimab-in-sle-first-in-class-efficacy-and-safety-results-demonstrating-proo.pdf](https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/eular/nipocalimab-in-sle-first-in-class-efficacy-and-safety-results-demonstrating-proo.pdf) [https://jcadonline.com/wp-content/uploads/Whats-New-in-Cutaneous-Lupus-Erythematosus-Guidelines-Biologics-and-Beyond.pdf](https://jcadonline.com/wp-content/uploads/Whats-New-in-Cutaneous-Lupus-Erythematosus-Guidelines-Biologics-and-Beyond.pdf) Immunovant’s Phase 2 trial: [https://clinicaltrials.gov/study/NCT06980805#study-overview](https://clinicaltrials.gov/study/NCT06980805#study-overview)